Boston Laser to Offer New Treatment for Keratoconus in New England

Share Article

Boston Laser is on the leading edge of new treatment for keratoconus, a sight debilitating disease

“Keratoconus affects approximately 1 in 2,000 Americans in the United States. We are delighted to finally be able to provide a proven approach to treating this debilitating disease,” says Samir Melki MD PhD, founder and Medical Director of Boston Laser.

Boston Laser is now offering a novel treatment for Keratoconus following its approval by the U.S Food and Drug Administration (FDA). The treatment consists of the application of Riboflavin, a vitamin, to the cornea. This, combined with UV light, leads to the stiffening of the collagen fibers which in turn strengthens the cornea to slow the progression of keratoconus.

Keratoconus is the continuous thinning and alteration of the cornea. Over time, the progression of the disease can lead to vision loss necessitating a corneal transplantation. “Keratoconus affects approximately 1 in 2,000 Americans in the United States. We are delighted to finally be able to provide a proven approach to treating this debilitating disease,” says Samir Melki MD PhD, founder and Medical Director of Boston Laser.

Boston Laser already has extensive experience through its involvement in an FDA cross-linking trial, and is currently one of two providers in the state of Massachusetts that can offer this type of treatment for keratoconus.

Boston Laser was founded in 2000 by Dr. Samir Melki. It is an academic private practice that focuses on staying at the vanguard of eye care. Boston Laser has four main offices in Massachusetts located in Brookline, Lawrence, Medford and Wellesley.

For more information on cross-linking for keratoconus, or to see if you qualify for this innovative treatment, please contact Boston Laser directly at (617) 566-0062 or by visiting http://www.bostonlaser.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Daniela Procopio
Boston Laser
+1 (617) 566-0062 Ext: 335
Email >
Visit website